Literature DB >> 33219410

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.

Hirayuki Enomoto1, Yoshiyuki Ueno2, Yoichi Hiasa3, Hiroki Nishikawa1,4, Shuhei Hige5, Yasuhiro Takikawa6, Makiko Taniai7, Toru Ishikawa8, Kohichiroh Yasui9, Akinobu Takaki10, Koichi Takaguchi11, Akio Ido12, Masayuki Kurosaki13, Tatsuya Kanto14, Shuhei Nishiguchi15,16.   

Abstract

BACKGROUND: We recently reported the real-world changes in the etiologies of liver cirrhosis (LC) based on nationwide survey data and assessed the etiologies of LC with hepatocellular carcinoma (HCC).
METHODS: Fifty-five participants from 68 institutions provided data on 23,637 patients with HCC-complicated LC. The changing trends in etiologies were assessed. We further analyzed the data from 29 hospitals that provided the annual number of newly identified HCC-complicated LC patients from 2008 to 2016 (N = 9362) without any missing years and assessed the transition in the real number of newly identified HCC-complicated LC cases.
RESULTS: In the overall cohort, hepatitis C virus (HCV) infection (60.3%) and hepatitis B virus (HBV) infection (12.9%) were the leading and third-most common causes of HCC-complicated LC in Japan, respectively. HCV infection was found to be the leading cause throughout Japan. The rate of viral hepatitis-related HCC decreased from 85.3 to 64.4%. Among non-viral etiologies, notable increases were observed in nonalcoholic steatohepatitis (NASH)-related HCC (from 1.5 to 7.2%) and alcoholic liver disease (ALD)-related HCC (from 8.5 to 18.6%). Regarding the real number of newly diagnosed patients, the number of patients with viral hepatitis-related HCC decreased, while the number of patients with non-viral HCC, particularly NASH-related HCC, increased.
CONCLUSIONS: Viral hepatitis has remained the main cause of HCC in Japan. However, the decrease in viral hepatitis-related HCC, particularly HCV-related HCC highly contributed to the etiological changes. In addition, the increased incidence of non-viral HCC, particularly NASH-related HCC, was involved in the changing etiologies of HCC-complicated LC in Japan.

Entities:  

Keywords:  Cirrhosis; Etiology; Hepatocellular carcinoma; Nationwide survey

Mesh:

Year:  2020        PMID: 33219410      PMCID: PMC7862502          DOI: 10.1007/s00535-020-01748-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  25 in total

1.  Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update.

Authors: 
Journal:  Hepatol Res       Date:  2020-07-15       Impact factor: 4.288

2.  The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.

Authors:  Kazuyuki Mizuno; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Takashi Kumada; Yasuhiro Sone; Junko Tanaka
Journal:  J Gastroenterol       Date:  2019-06-03       Impact factor: 7.527

3.  Recent trend of clinical features in patients with hepatocellular carcinoma.

Authors:  Yuko Nagaoki; Hideyuki Hyogo; Hiroshi Aikata; Mio Tanaka; Noriaki Naeshiro; Takashi Nakahara; Yoji Honda; Daisuke Miyaki; Tomokazu Kawaoka; Shintaro Takaki; Akira Hiramatsu; Koji Waki; Michio Imamura; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2011-12-13       Impact factor: 4.288

4.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

5.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

Review 6.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

7.  Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.

Authors:  Chung-Feng Huang; Etsuko Iio; Dae Won Jun; Eiichi Ogawa; Hidenori Toyoda; Yao-Chun Hsu; Hiroaki Haga; Shinji Iwane; Masaru Enomoto; Dong Hyun Lee; Grace Wong; Chen-Hua Liu; Toshifumi Tada; Wan-Long Chuang; Ramsey Cheung; Jun Hayashi; Cheng-Hao Tseng; Satoshi Yasuda; Sally Tran; Leslie Kam; Linda Henry; Jae Yoon Jeong; Hideyuki Nomura; Seung Ha Park; Makoto Nakamuta; Jee-Fu Huang; Chi-Ming Tai; Gin-Ho Lo; Mei-Hsuan Lee; Hwai-I Yang; Jia-Horng Kao; Akihiro Tamori; Yuichiro Eguchi; Yoshiyuki Ueno; Norihiro Furusyo; Yasuhito Tanaka; Ming-Lung Yu; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2019-08-28       Impact factor: 9.029

8.  Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.

Authors:  Toshie Mashiba; Kouji Joko; Masayuki Kurosaki; Hironori Ochi; Chitomi Hasebe; Takehiro Akahane; Tetsuro Sohda; Keiji Tsuji; Akeri Mitsuda; Hiroyuki Kimura; Ryoichi Narita; Chikara Ogawa; Koichiro Furuta; Masaya Shigeno; Hiroaki Okushin; Hiroshi Ito; Atsunori Kusakabe; Takashi Satou; Chiharu Kawanami; Ryo Nakata; Haruhiko Kobashi; Takashi Tamada; Yasushi Ide; Hitoshi Yagisawa; Atsuhiro Morita; Tomomichi Matsushita; Kazuhiko Okada; Namiki Izumi
Journal:  Hepatol Res       Date:  2019-06-14       Impact factor: 4.288

Review 9.  Chronic Hepatitis B Infection: A Review.

Authors:  Lydia S Y Tang; Emily Covert; Eleanor Wilson; Shyam Kottilil
Journal:  JAMA       Date:  2018-05-01       Impact factor: 56.272

10.  Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.

Authors:  Masatoshi Kudo; Namiki Izumi; Shoji Kubo; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Tadatoshi Takayama
Journal:  Hepatol Res       Date:  2020-01-05       Impact factor: 4.288

View more
  7 in total

1.  Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".

Authors:  Hirayuki Enomoto; Shuhei Nishiguchi
Journal:  J Gastroenterol       Date:  2021-03-11       Impact factor: 7.527

2.  Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan.

Authors:  Hideki Hagiwara; Yoshiki Ito; Takashi Ohta; Yasutoshi Nozaki; Takayuki Iwamoto; Atsushi Hosui; Naoki Hiramatsu; Yuki Tahata; Ryotaro Sakamori; Hayato Hikita; Norio Hayashi
Journal:  JGH Open       Date:  2022-05-18

3.  Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus.

Authors:  Yoshihiro Shimono; Hirayuki Enomoto; Nobuhiro Aizawa; Tomoyuki Takashima; Naoto Ikeda; Yukihisa Yuri; Aoi Fujiwara; Kohei Yoshihara; Ryota Yoshioka; Shoki Kawata; Shogo Ota; Ryota Nakano; Hideyuki Shiomi; Takashi Nishimura; Hiroko Iijima
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 4.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

5.  Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019.

Authors:  Masahito Nakano; Hiroshi Yatsuhashi; Shigemune Bekki; Yuko Takami; Yasuhito Tanaka; Yoko Yoshimaru; Koichi Honda; Yasuji Komorizono; Masaru Harada; Michihiko Shibata; Shotaro Sakisaka; Satoshi Shakado; Kenji Nagata; Tomoharu Yoshizumi; Shinji Itoh; Tetsuro Sohda; Satoshi Oeda; Kazuhiko Nakao; Ryu Sasaki; Tsutomu Yamashita; Akio Ido; Seiichi Mawatari; Makoto Nakamuta; Yoshifusa Aratake; Shuichi Matsumoto; Tatsuji Maeshiro; Takashi Goto; Takuji Torimura
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

Review 6.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

Review 7.  Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.

Authors:  Masayuki Ueno; Haruhiko Takeda; Atsushi Takai; Hiroshi Seno
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.